ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0408

Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus

Julia Harris1, Susan Parish2, Michelle Manaskie2 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO

Meeting: ACR Convergence 2025

Keywords: quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There is a profound need to improve outcomes in children with systemic lupus erythematosus (SLE) given this disease is complicated by significant morbidity. Disparities in pediatric SLE (pSLE) outcomes are also rampant and may be better understood through a social drivers of health (SDOH) framework. SDOH are conditions in the environment where patients live, work, learn, and play, and they have been found to have a significant influence on health outcomes. Children’s Mercy Integrated Care Solutions (CMICS), our hospital’s population health management subsidiary, has created Lift Up KC, a social care platform linking patients and families to community resources. Our patients with SLE have low disease activity at 85.7% of visits, and 67.7% of SLE visits have a low patient/parent global assessment of overall wellbeing. We aimed to increase the percent of patients with SLE seen in the rheumatology clinic who receive screening of SDOH at follow-up clinic visits from 0% to 50% by June 30, 2025. We also aimed to increase the percent of patients with SLE who have low disease activity (based on SLEDAI-2k) from 85.7% to 90% by June 30, 2025.

Methods: We utilized quality improvement (QI) methodology including QI tools such as a key driver diagram (Figure 1), fishbone diagram, process map, and failure modes effects analysis. Our outcome measures include percent of SLE visits with low disease activity (SLEDAI-2k ≤4) and low patient/parent global assessment of overall wellbeing score (≤2). Process measures include SDOH screening being sent, completion of screening form, screen positive rate, patients/parents wanting assistance, successful referral to a community-based organization, and no-show rate. Our balancing measure is an average physician satisfaction score. Interventions included meeting with local experts, education on our screening tool and referral process, identification of a super user, education to physicians and nurses, and partnership with social work. We evaluated our data on run charts.

Results: SDOH screening started in November 2024 and the screening tool has been sent to 100% of patients/families since this time. The form completion rate is 63.9%. Social needs identified in 1-3 screens per month and help wanted 0-4 times per month for a positive screen rate of 9.1-28.6% (median 15%) (Figure 2). All families wanting assistance were referred to a partner community organization. No show visits and last-minute cancellations occurred in 16.7% of scheduled SLE visits. Our outcome measures remained stable – 85.7% of visits with low disease activity (Figure 3) and 67.7% with low patient/parent global assessment of overall wellbeing.

Conclusion: We have successfully implemented SDOH screening in our SLE population. Although outcomes remain stable at this point, we hope to improve the care of SLE patients over time by addressing social needs that can have a significant impact on their disease and overall health.

Supporting image 1Figure 1. Key driver diagram for social drivers of health screening in patients with SLE.

Supporting image 2Figure 2. Run chart of positive SDOH screens.

Supporting image 3Figure 3. Annotated run chart of SLE visits with low disease activity.


Disclosures: J. Harris: None; S. Parish: None; M. Manaskie: None; A. Cooper: None.

To cite this abstract in AMA style:

Harris J, Parish S, Manaskie M, Cooper A. Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/implementing-social-drivers-of-health-screening-for-patients-with-pediatric-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementing-social-drivers-of-health-screening-for-patients-with-pediatric-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology